Optimizing cell lines for a Hepatitis B vaccine
Official title: Task V24: Cell line optimization and pre-master bank generation for a Hepatitis B Virus (HBV) vaccine
Funded at International AIDS Vaccine Initiative · NIH-10937202 · Data updated 2026-11-12
This study is working on creating a new vaccine to help protect people from Hepatitis B, and it aims to make sure the vaccine is safe and effective for everyone who might need it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International AIDS Vaccine Initiative NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2023 |
| Award (this year) | $21,289 |
| NIH project number | 272201800010I-P00002-759302000003-2 |
| Project ID | NIH-10937202 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of Hepatitis B infection, including those with chronic liver disease or those in high-risk populations.
✕Less likely to help
Patients who are already vaccinated against Hepatitis B or those with a history of severe allergic reactions to vaccine components may not benefit from this research.
What this research studies
This research focuses on developing and optimizing cell lines to produce a vaccine against Hepatitis B Virus (HBV). It involves planning and assessing the feasibility of vaccine production, ensuring compliance with manufacturing standards, and preparing for clinical trials. The project aims to create a reliable vaccine that can be used to protect individuals from HBV, a significant public health concern. Patients may benefit from the eventual availability of a new vaccine that could prevent HBV infection.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that effectively prevents Hepatitis B Virus infection.
How similar studies have gone: Other research has shown success in developing vaccines using optimized cell lines, indicating that this approach has potential.
Where this research is happening
-
International AIDS Vaccine Initiative
New York, United States Active
Researchers
- Principal investigator: Hassel, Thomas — International AIDS Vaccine Initiative
- Study coordinator: Hassel, Thomas
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.